These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

139 related articles for article (PubMed ID: 20041959)

  • 21. Early factor VIII exposure and subsequent inhibitor development in children with severe haemophilia A.
    Chalmers EA; Brown SA; Keeling D; Liesner R; Richards M; Stirling D; Thomas A; Vidler V; Williams MD; Young D;
    Haemophilia; 2007 Mar; 13(2):149-55. PubMed ID: 17286767
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Intracranial haemorrhage in severe haemophilia: prevalence and outcome in a developing country.
    Ghosh K; Nair AP; Jijina F; Madkaikar M; Shetty S; Mohanty D
    Haemophilia; 2005 Sep; 11(5):459-62. PubMed ID: 16128888
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Inhibitors of factor VIII in hemophilia.
    Lacroix-Desmazes S; Dimitrov JD; Repesse Y
    N Engl J Med; 2009 Jul; 361(3):308; author reply 310. PubMed ID: 19605840
    [No Abstract]   [Full Text] [Related]  

  • 24. Intracranial haemorrhage in haemophilia A and B.
    Ljung RC
    Br J Haematol; 2008 Feb; 140(4):378-84. PubMed ID: 18081890
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Prophylaxis for severe haemophilia: clinical challenges in the absence as well as in the presence of inhibitors.
    Fischer K; Valentino L; Ljung R; Blanchette V
    Haemophilia; 2008 Jul; 14 Suppl 3():196-201. PubMed ID: 18510542
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The prophylactic use of porcine factor VIII.
    Hilgartner MW
    Semin Hematol; 1994 Apr; 31(2 Suppl 4):39-40. PubMed ID: 7939773
    [No Abstract]   [Full Text] [Related]  

  • 27. [Results of a cooperative programme of profilactic treatment for haemophilia A and B (author's transl)].
    Sangre (Barc); 1978; 23(5B):780-92. PubMed ID: 725718
    [No Abstract]   [Full Text] [Related]  

  • 28. Factor VIII prophylaxis for adult patients with severe haemophilia A: results of a US survey of attitudes and practices.
    Walsh CE; Valentino LA
    Haemophilia; 2009 Sep; 15(5):1014-21. PubMed ID: 19493018
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Long-term prophylaxis in patients with factor XIII deficiency complicated by intracranial haemorrhage in Iran.
    Eshghi P; Mahjour SB; Naderi M; Dehbozorgian J; Karimi M
    Haemophilia; 2010 Mar; 16(2):383-5. PubMed ID: 19878334
    [No Abstract]   [Full Text] [Related]  

  • 30. Factor VIII half-life and intensity of treatment in hemophilic patients.
    Vicente V
    Haematologica; 2005 Apr; 90(4):437. PubMed ID: 15820932
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Occurrence of inhibitors in previously untreated or minimally treated patients with haemophilia A after exposure to a plasma-derived solvent-detergent factor VIII concentrate.
    Gringeri A; Monzini M; Tagariello G; Scaraggi FA; Mannucci PM;
    Haemophilia; 2006 Mar; 12(2):128-32. PubMed ID: 16476086
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Immune tolerance induction with high von Willebrand factor/factor VIII content ratio concentrate in children with haemophilia A and high-responding inhibitor.
    Platokouki H; Pergantou H; Xafaki P; Komitopoulou A; Aronis S
    Haemophilia; 2009 Mar; 15(2):617-9. PubMed ID: 19175417
    [No Abstract]   [Full Text] [Related]  

  • 33. Assessment of incidence of inhibitors in patients with haemophilia.
    van der Bom JG; ter Avest P; Van den Berg HM; Psaty BM; Weiss NS
    Haemophilia; 2009 May; 15(3):707-11. PubMed ID: 19432923
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Emerging clinical concerns in the ageing haemophilia patient.
    Konkle BA; Kessler C; Aledort L; Andersen J; Fogarty P; Kouides P; Quon D; Ragni M; Zakarija A; Ewenstein B
    Haemophilia; 2009 Nov; 15(6):1197-209. PubMed ID: 19686466
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Impact of choice of treatment for bleeding episodes on inhibitor outcome in patients with mild/moderate hemophilia a and inhibitors.
    d'Oiron R; Volot F; Reynaud J; Peerlinck K; Goudemand J; Guérois C; Rothschild C; Chambost H; Borel-Derlon A; Roussel-Robert V; Marquès-Verdier A; Lienhart A; Berthier AM; Moreau P; Lambert T;
    Semin Hematol; 2006 Jan; 43(1 Suppl 1):S3-9. PubMed ID: 16427382
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Tyr2105Cys mutation in exon 22 of FVIII gene is a risk factor for the development of inhibitors in patients with mild/moderate haemophilia A.
    Franchini M; Girelli D; Olivieri O; Castaman G; Lippi G; Poli G; Salvagno GL; Tagariello G; Giuffrida A; de Gironcoli M; Morfini M; Berntorp E; Gandini G
    Haemophilia; 2006 Jul; 12(4):448-51. PubMed ID: 16834751
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Analysis of cytokine genes polymorphism as markers for inhibitor development in haemophilia A.
    Chaves D; Belisário A; Castro G; Santoro M; Rodrigues C
    Int J Immunogenet; 2010 Apr; 37(2):79-82. PubMed ID: 20082647
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Comparing prophylaxis with episodic treatment in haemophilia A: implications for clinical practice.
    Manco-Johnson M
    Haemophilia; 2007 Sep; 13 Suppl 2():4-9. PubMed ID: 17685917
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Coincident classic hemophilia and "idiopathic" thrombocytopenic purpura in patients under treatment with concentrates of antihemophilic factor (factor VIII).
    Ratnoff OD; Menitove JE; Aster RH; Lederman MM
    N Engl J Med; 1983 Feb; 308(8):439-42. PubMed ID: 6401839
    [No Abstract]   [Full Text] [Related]  

  • 40. Prophylaxis and complications in hemophilia. Introductory remarks.
    Harris CE
    Bibl Haematol; 1970; 34():97-103. PubMed ID: 5436358
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.